The world’s first FD treatment, Acofide demonstrated efficacy in FD patients diagnosed by the international diagnostic criteria for functional gastrointestinal diseases, the Rome III.
Both the companies will jointly promote the first FD therapy to increase the awareness of the disease and commercialization of the medication.
Believed to improve the quality of life of the patients, the new chemical entity Acotiamide hydrochloride hydrate originated by Zeria inhibits peripheral acetylcholinesterase activities.
Acofide, that is being launched first in Japan, is designed to improve impaired gastric motility, delayed gastric emptying and thereby FD symptoms, including postprandial fullness, upper abdominal bloating, and early satiation.